World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
120
Citations
82278
World Ranking
543
National Ranking
324

Medicine

D-Index
125
Citations
88361
World Ranking
3014
National Ranking
1666

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Lecia V. Sequist is affiliated with Harvard University in the United States. Their research primarily focuses on lung cancer, with a strong emphasis on lung cancer treatments, mutations, and diagnostics. Their expertise spans multiple fields including Medicine, Biochemistry, Genetics and Molecular Biology, with significant contributions in subfields such as Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Cancer Research.

Themes central to their research include lung cancer treatments and mutations, lung cancer diagnosis and treatment, colorectal cancer treatments and studies, cancer genomics and diagnostics, lung cancer research studies, radiomics and machine learning in medical imaging, and gastric cancer management and outcomes.

Frequent coauthors of Lecia V. Sequist include:

  • Zofia Piotrowska
  • W. Marston Linehan
  • Mari Mino-Kenudson
  • Aaron N. Hata
  • Justin F. Gainor

Their publications are often found in the following venues:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • JTO Clinical and Research Reports
  • Annals of Oncology

Notable recent papers authored or co-authored by Lecia V. Sequist include:

  • "Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study" (2020) published in The Lancet Oncology
  • "Lung cancer" (2021) published in The Lancet
  • "Integrating genomic features for non-invasive early lung cancer detection" (2020) published in Nature
  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer" (2021) published in Journal of Thoracic Oncology
  • "Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management" (2022) published in Nature Reviews Clinical Oncology

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Isolation of rare circulating tumour cells in cancer patients by microchip technology.

    Sunitha Nagrath;Lecia V. Sequist;Shyamala Maheswaran;Daphne W. Bell;Daphne W. Bell

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  • Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    Min Yu;Aditya Bardia;Ben S. Wittner;Shannon L. Stott

  • Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

    Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus

  • Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

    Shannon L. Stott;Chia Hsien Hsu;Chia Hsien Hsu;Chia Hsien Hsu;Dina I. Tsukrov;Min Yu

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

    Emre Ozkumur;Ajay M. Shah;Jordan C. Ciciliano;Benjamin L. Emmink

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

  • Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

    James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  • First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

    Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  • Acquired resistance to TKIs in solid tumours: learning from lung cancer

    D. Ross Camidge;William Pao;Lecia V. Sequist

  • Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Matthew G Oser;Matthew J Niederst;Lecia V Sequist;Jeffrey A Engelman

Frequent Co-Authors

Daniel A. Haber
Daniel A. Haber Harvard University
Alice T. Shaw
Alice T. Shaw Harvard University
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Alona Muzikansky
Alona Muzikansky Harvard University
Mehmet Toner
Mehmet Toner Harvard University
Shyamala Maheswaran
Shyamala Maheswaran Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Heather A. Wakelee
Heather A. Wakelee Stanford University
Justin F. Gainor
Justin F. Gainor Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but seeking alternative or complementary career pathways, online degrees offer flexible options that match diverse goals. A popular route is earning a pharm d online programs, preparing you for a career as a licensed pharmacist. These programs allow students to gain clinical training and pharmacy knowledge remotely, which is ideal for working professionals.

Tech-focused students may find value in a him degree online. Health information management (HIM) roles play a crucial part in managing patient data and ensuring healthcare systems run smoothly. Meanwhile, obtaining a medical billing and coding certification online can quickly launch your career in the fast-growing field of health administration, enabling flexible work environments and strong job prospects.

If your passion remains in direct patient care but you want more autonomy than a traditional nursing role, explore nurse practitioner programs online. These advanced degrees offer clinical expertise and leadership opportunities, all while maintaining the flexibility of distance learning. Together, these online pathways provide accessible, rewarding options in the healthcare sector.

Best Scientists Citing Lecia V. Sequist

Trending Scientists

Recently Published Articles